Mark R. Barakat, MD: RGX-314 for Diabetic Retinopathy in ALTITUDE Study

First-year results from ALTITUDE suggest RGX-314 was well-tolerated and provided meaningful improvements in disease severity at dose levels 1 and 2.

Related Keywords

Arizona ,United States ,California ,San Francisco ,American ,Mark Barakat ,American Academy Of Ophthalmology ,Annual American Academy ,Retina Consultants ,